Tempest Therapeutics, Inc. TPST 深 滬
交易中 09-25 10:29:38 美东时间
0.8511
+0.001
+0.13%
華盛通- 最 高0.8946
- 今 開0.8608
- 成交量 6.44万股
- 最 低 0.8496
- 昨 收 0.85
- 總市值 1407.70万
- 52周最高 12.23
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.7432
- 委 比 -98.35%
- 總股本 1653.98万
- 歷史最高 3381.30
- 量 比 0.25
- 振 幅 5.29%
- 歷史最低 0.7432
- 每 手 1
- 風險率 3.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
今天 15:55
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
09-24 23:56
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) are trading sharply higher Wednesday morning as investors respond positively to a strategic agreement expanding the company’s next-generation cell therapy pipeline. Tempest Therapeutics shares are powering higher. What’s driving TPST stock higher? Exc...
09-16 23:25
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. According to the announcement, the agreement gives Tempest an exclusi...
09-16 17:04
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 83.57 percent increase over losses of $(2.07) per share from the same period last year.
08-14 04:42
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and oncology indications Senlang Biotechnology, a clinica...
07-21 19:08
Tempest Therapeutics shares are trading lower after the company announced the exercise of warrants to buy approximately 1.2 million shares at a reduced exercise price of $1.73 per share.
Tempest Therapeutics shares are trading lower after the company announced the e...
05-30 01:09
Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.28) by 78.57 percent. This is a 84.18 percent increase over losses of $(3.16) per share
05-15 05:23
Tempest Therapeutics Reaches Milestone In TPST-2003 Manufacturing Process
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma ("rrMM") through a parallel dual-targeting CAR
04-22 20:10
Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(3.52) by 82.39 percent. This is a 87.77 percent increase over losses of $(5.07) per share
03-30 21:06
